MYL2
ENSG00000111245
Target class
Unclassified protein
Chromosome
12
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CMH10
- Target name
- MYL2
- Gene name
- Myosin light chain 2
- Gene symbol
- MYL2
- Protein name
- Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC-2) (MLC-2v) (Cardiac myosin light chain 2) (Myosin light chain 2, slow skeletal/ventricular muscle isoform) (MLC-2s/v) (Ventricular myosin light chain 2)
- Gene biotype
- Protein coding
- Gene family
- Myosin light chains, class 2
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 50
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 14,495.3
- Tissue specificity (Gini)
- 0.961
- Tissue specificity (tau)
- 0.984
- KEGG gene identifiers
- hsa:4633
- Reactome pathways
- R-HSA-390522
- Protein interaction confidence
- 0.874693
- Protein interaction partners
- 75
- End position
- 111052434
- Start position
- 110909996
- Chromosome
- 12
- Strand
- Reverse
- Cytoplasm, myofibril, sarcomere, A band .
- Tissue specificity (tau)
- 0.984023
- Expression inequality (Gini)
- 0.960946
Expression in transcripts per million
- Heart - Left Ventricle
- 14,495.3
- Muscle - Skeletal
- 12,092.5
- Heart - Atrial Appendage
- 47.07
- Minor Salivary Gland
- 7.83
- Artery - Aorta
- 7.36
Expression in transcripts per million
- Heart - Left Ventricle14,495.3
- Muscle - Skeletal12,092.5
- Heart - Atrial Appendage47.07
- Minor Salivary Gland7.83
- Artery - Aorta7.36
- Artery - Coronary5.53
- Nerve - Tibial5.38
- Cells - EBV-transformed lymphocytes4.86
- Artery - Tibial4.77
- Lung4.45
- Skin - Sun Exposed (Lower leg)4.18
- Skin - Not Sun Exposed (Suprapubic)3.89
- Adipose - Subcutaneous3.78
- Esophagus - Gastroesophageal Junction3.7
- Thyroid3.68
- Colon - Sigmoid3.6
- Adipose - Visceral (Omentum)3.42
- Esophagus - Muscularis3.41
- Prostate3.17
- Vagina3.13
- Breast - Mammary Tissue3.11
- Brain - Cortex2.99
- Whole Blood2.84
- Uterus2.71
- Brain - Cerebellum2.66
And 29 more, listed on the interactive page.
- GO:0006942
- GO:0030308
- GO:0055010
- GO:0005829
- GO:0005856
- GO:0015629
- GO:0016459
- GO:0030017
- GO:0097512
- GO:0003785
- GO:0005509
- GO:0005515
- GO:0008307
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator